Pradžia › Krono liga › Texas › Tyler
Krono liga klinikiniai tyrimai Tyler, TX
16 tyrimai dėl Krono liga ieško dalyvių vietose Tyler ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Renkami dalyviai3 fazė
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Renkami dalyviai3 fazė
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Renkami dalyviai2 fazė
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Renkami dalyviai3 fazė
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Renkami dalyviai2/3 fazė
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Renkami dalyviai2 fazė
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Renkami dalyviai3 fazė
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Renkami dalyviai3 fazė
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Renkami dalyviai3 fazė
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Renkami dalyviai2 fazė
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Renkami dalyviai4 fazė
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Renkami dalyviai3 fazė
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Renkami dalyviai3 fazė
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Renkami dalyviai2 fazė
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Renkami dalyviai2 fazė
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Renkami dalyviai2 fazė
- Mirador Therapeutics Selected Site, Tyler
Krono liga tyrimai kituose miestuose
- New York City, NY35 tyrimai
- Cleveland, OH19 tyrimai
- St. Louis, MO19 tyrimai
- Boston, MA19 tyrimai
- Miami, FL19 tyrimai
- Orlando, FL17 tyrimai
- Houston, TX17 tyrimai
- Atlanta, GA17 tyrimai
- San Diego, CA15 tyrimai
- San Antonio, TX15 tyrimai
- Los Angeles, CA15 tyrimai
- Philadelphia, PA13 tyrimai
Kiti tyrimai Tyler
- Nedidelinių ląstelių plaučių vėžys20 tyrimai
- Opinis kolitas14 tyrimai
- Storosios ir tiesiosios žarnos vėžys8 tyrimai
- Širdies nepakankamumas8 tyrimai
- Vėžys (visų tipų)7 tyrimai
- Kiaušidžių vėžys7 tyrimai
- Endometrio vėžys6 tyrimai
- Galvos ir kaklo plokščiųjų ląstelių karcinoma6 tyrimai
- Krūties vėžys6 tyrimai
- Metastatinis vėžys5 tyrimai
- Uždegiminė žarnyno liga5 tyrimai
- Lėtinė limfocitinė leukemija5 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.